Literature DB >> 31316176

WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway.

Rui Ding1,2, Xin Wang1, Wei Chen1, Zhi Li1, Ai-Li Wei1, Qing-Bin Wang1, Ai-Hua Nie1, Li-Li Wang3,4.   

Abstract

Recently, inhibitor of apoptosis proteins (IAPs) and some IAP antagonists were found to regulate autophagy, but the underlying mechanisms remain unclear. WX20120108 is an analogue of GDC-0152 (a known IAP antagonist) and displays more potent anti-tumor and autophagy-regulating activity in tumor cells, we investigated the regulatory mechanisms underlying WX20120108-induced autophagy. Using molecular docking and fluorescence polarization anisotropy (FPA) competitive assay, we first demonstrated that WX20120108, acting as an IAP antagonist, bound to the XIAP-BIR3, XIAP BIR2-BIR3, cIAP1 BIR3, and cIAP2 BIR3 domains with high affinities. In six cancer cell lines, WX20120108 inhibited the cell proliferation with potencies two to ten-fold higher than that of GDC-0152. In HeLa and MDA-MB-231 cells, WX20120108 induced caspase-dependent apoptosis and activated TNFα-dependent extrinsic apoptosis. On the other hand, WX20120108 induced autophagy in HeLa and MDA-MB-231 cells in dose- and time-dependent manners. We revealed that WX20120108 selectively activated Foxo3, evidenced by Foxo3 nuclear translocation in both gene modified cell line and HeLa cells, as well as the upregulated expression of Foxo3-targeted genes (Bnip3, Pik3c3, Atg5, and Atg4b), which played a key role in autophagy initiation. WX20120108-induced autophagy was significantly suppressed when Foxo3 gene was silenced. WX20120108 dose-dependently increased the generation of reactive oxygen species (ROS) in HeLa cells, and WX20120108-induced Foxo3 activation was completely blocked in the presence of catalase, a known ROS scavenger. However, WX20120108-induced ROS generation was not affected by cIAP1/2 or XIAP gene silencing. In conclusion, WX20120108-induced autophagy relies on activating ROS-Foxo3 pathway, which is independent of IAPs. This finding provides a new insight into the mechanism of IAP antagonist-mediated regulation of autophagy.

Entities:  

Keywords:  Foxo3; GDC-0152; IAP antagonists; ROS; WX20120108; apoptosis; autophagy; carcinoma cells; catalase

Mesh:

Substances:

Year:  2019        PMID: 31316176      PMCID: PMC6889436          DOI: 10.1038/s41401-019-0253-5

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  73 in total

1.  Structural basis of caspase-7 inhibition by XIAP.

Authors:  J Chai; E Shiozaki; S M Srinivasula; Q Wu; P Datta; E S Alnemri; Y Shi; P Dataa
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

2.  Structural basis for the inhibition of caspase-3 by XIAP.

Authors:  S J Riedl; M Renatus; R Schwarzenbacher; Q Zhou; C Sun; S W Fesik; R C Liddington; G S Salvesen
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

Review 3.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

4.  NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP.

Authors:  C Sun; M Cai; A H Gunasekera; R P Meadows; H Wang; J Chen; H Zhang; W Wu; N Xu; S C Ng; S W Fesik
Journal:  Nature       Date:  1999-10-21       Impact factor: 49.962

5.  AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.

Authors:  Melissa K Brunckhorst; Dimitry Lerner; Shaomeng Wang; Qin Yu
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

6.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

Authors:  C Y Wang; M W Mayo; R G Korneluk; D V Goeddel; A S Baldwin
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

Review 7.  Smac mimetics as IAP antagonists.

Authors:  Simone Fulda
Journal:  Semin Cell Dev Biol       Date:  2014-12-27       Impact factor: 7.727

8.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.

Authors:  I Tamm; S M Kornblau; H Segall; S Krajewski; K Welsh; S Kitada; D A Scudiero; G Tudor; Y H Qui; A Monks; M Andreeff; J C Reed
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

Review 9.  The inhibitors of apoptosis (IAPs) as cancer targets.

Authors:  Allison M Hunter; Eric C LaCasse; Robert G Korneluk
Journal:  Apoptosis       Date:  2007-09       Impact factor: 4.677

Review 10.  The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy.

Authors:  M C de Almagro; D Vucic
Journal:  Exp Oncol       Date:  2012-10
View more
  6 in total

Review 1.  Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics.

Authors:  Nicole Bata; Nicholas D P Cosford
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-03

Review 2.  Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Authors:  Fu Peng; Minru Liao; Rui Qin; Shiou Zhu; Cheng Peng; Leilei Fu; Yi Chen; Bo Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 3.  Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE.

Authors:  Chun Hei Antonio Cheung; Yung-Chieh Chang; Tzu-Yu Lin; Siao Muk Cheng; Euphemia Leung
Journal:  J Biomed Sci       Date:  2020-02-05       Impact factor: 8.410

4.  ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival.

Authors:  Hao Zhang; Peng Xia; Jie Liu; Zhang Chen; Weijie Ma; Yufeng Yuan
Journal:  Int J Biol Sci       Date:  2021-10-25       Impact factor: 6.580

5.  Doramectin inhibits glioblastoma cell survival via regulation of autophagy in vitro and in vivo.

Authors:  Chen Chen; Hongsheng Liang; Ruirui Qin; Xin Li; Liwei Wang; Songlin Du; Zhihao Chen; Xiangxi Meng; Zhonghua Lv; Qing Wang; Jing Meng; Aili Gao
Journal:  Int J Oncol       Date:  2022-02-09       Impact factor: 5.650

Review 6.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

Authors:  Minru Liao; Rui Qin; Wei Huang; Hong-Ping Zhu; Fu Peng; Bo Han; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.